Target validation in silico: does the virtual patient cure the pharma pipeline?

Area of Science:

• Pharmacology
• Computational Biology
• Biotechnology

Background:

• Genomic advancements offer numerous therapeutic targets, yet drug development pipelines show limited output increase.
• The complexity of biological systems and molecule interactions is often underestimated, leading to translation failures.
• Preclinical (in vitro, in vivo) results frequently do not predict human efficacy or toxicity.

Discussion:

• Biosimulation utilizes mechanistic, predictive models to represent complex molecular and cellular dynamics.
• The 'virtual patient' concept models specific pathophysiological behaviors for predictive analysis.
• Biosimulation aids in target identification, target validation, and clinical development phases.

Key Insights:

• Biosimulation addresses critical issues in drug development, such as unforeseen toxicity and efficacy problems.
• Virtual patients offer a powerful tool for understanding disease mechanisms and predicting drug responses.
• Mechanistic modeling enhances the predictive power of preclinical data for human applications.

Outlook:

• Widespread adoption of biosimulation methods requires addressing challenges in model validation and acceptance.
• Continued development of biosimulation platforms will be crucial for accelerating therapeutic interventions.
• Integrating virtual patient models into drug discovery workflows promises to improve success rates and reduce costs.